About Rempex Pharmaceuticals
Rempex Pharmaceuticals is a company based in San Diego (United States) founded in 2011 was acquired by The Medicines Company in December 2013.. Rempex Pharmaceuticals has raised $67.5 million across 2 funding rounds from investors including HHS, Orbimed and Frazier Healthcare Partners. Rempex Pharmaceuticals operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rempex Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$67.5 M (USD)
in 2 rounds
-
Latest Funding Round
$407.41 K (USD), Grant
May 01, 2012
-
Investors
HHS
& 6 more
-
Employee Count
Employee Count
-
Acquired by
The Medicines Company
(Dec 04, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Rempex Pharmaceuticals
Rempex Pharmaceuticals has successfully raised a total of $67.5M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $407.41 thousand completed in May 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $407,413
-
First Round
First Round
(09 Nov 2011)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2012 | Amount | Grant - Rempex Pharmaceuticals | Valuation |
investors |
|
| Nov, 2011 | Amount | Series B - Rempex Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rempex Pharmaceuticals
Rempex Pharmaceuticals has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Orbimed and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Private markets investment management with strategies in equity, credit, and secondary investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rempex Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rempex Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rempex Pharmaceuticals Comparisons
Competitors of Rempex Pharmaceuticals
Rempex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rempex Pharmaceuticals
Frequently Asked Questions about Rempex Pharmaceuticals
When was Rempex Pharmaceuticals founded?
Rempex Pharmaceuticals was founded in 2011.
Where is Rempex Pharmaceuticals located?
Rempex Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Rempex Pharmaceuticals?
Daniel D Burgess is the current CEO of Rempex Pharmaceuticals.
Is Rempex Pharmaceuticals a funded company?
Rempex Pharmaceuticals is a funded company, having raised a total of $67.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $67.5M, raised on Nov 09, 2011.
What does Rempex Pharmaceuticals do?
Rempex Pharmaceuticals was founded in 2011 in San Diego, United States, within the pharmaceuticals sector. Operations center on discovering and developing new antibacterial drugs to address multi-drug resistant pathogens. The internal pipeline integrates proprietary formulations, pharmacokineticpharmacodynamic strategies, and novel potentiating agents with established antibiotics. Bacterial resistance mechanisms are targeted or inhibited directly. Acquisition by The Medicines Company took place in December 2013 for 464 million.
Who are the top competitors of Rempex Pharmaceuticals?
Rempex Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are Rempex Pharmaceuticals's investors?
Rempex Pharmaceuticals has 7 investors. Key investors include HHS, Orbimed, Frazier Healthcare Partners, The Medicines Company, and Adams Street Partners.